ICICI Bank Limited [IBN] Revenue clocked in at $12.47 billion, down -9.15% YTD: What’s Next?


ICICI Bank Limited [NYSE: IBN] price plunged by -2.86 percent to reach at -$0.53. The company report on April 12, 2022 that Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152).

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced that the Company was informed by the U.S. Food and Drug Administration (FDA) that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN™ (BBV152), OCU-002, on clinical hold. This is a result of the Company’s decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited’s (BBIL) manufacturing facility. We will work with the FDA to address any questions.

About Ocugen, Inc.Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

A sum of 11343393 shares traded at recent session while its average daily volume was at 12.39M shares. ICICI Bank Limited shares reached a high of $18.35 and dropped to a low of $17.925 until finishing in the latest session at $17.98.

The one-year IBN stock forecast points to a potential upside of 33.09. The average equity rating for IBN stock is currently 1.30, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on ICICI Bank Limited [IBN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBN shares is $26.87 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Bernstein have made an estimate for ICICI Bank Limited shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 14, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on January 16, 2018, representing the official price target for ICICI Bank Limited stock.

The Average True Range (ATR) for ICICI Bank Limited is set at 0.45, with the Price to Sales ratio for IBN stock in the period of the last 12 months amounting to 5.17. The Price to Book ratio for the last quarter was 2.72, with the Price to Cash per share for the same quarter was set at 7.12.

IBN Stock Performance Analysis:

ICICI Bank Limited [IBN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.31. With this latest performance, IBN shares dropped by -7.75% in over the last four-week period, additionally sinking by -12.89% over the last 6 months – not to mention a rise of 7.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBN stock in for the last two-week period is set at 35.37, with the RSI for the last a single of trading hit 28.41, and the three-weeks RSI is set at 39.51 for ICICI Bank Limited [IBN]. The present Moving Average for the last 50 days of trading for this stock 18.86, while it was recorded at 18.82 for the last single week of trading, and 19.62 for the last 200 days.

Insight into ICICI Bank Limited Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and ICICI Bank Limited [IBN] shares currently have an operating margin of +21.74. ICICI Bank Limited’s Net Margin is presently recorded at +15.94.

Return on Total Capital for IBN is now 10.04, given the latest momentum, and Return on Invested Capital for the company is 7.54. Return on Equity for this stock inclined to 14.79, with Return on Assets sitting at 1.51. When it comes to the capital structure of this company, ICICI Bank Limited [IBN] has a Total Debt to Total Equity ratio set at 88.77. Additionally, IBN Total Debt to Total Capital is recorded at 47.02, with Total Debt to Total Assets ending up at 9.22. Long-Term Debt to Equity for the company is recorded at 88.77, with the Long-Term Debt to Total Capital now at 47.02.

ICICI Bank Limited [IBN] Insider Position Details

There are presently around $11,732 million, or 20.20% of IBN stock, in the hands of institutional investors. The top three institutional holders of IBN stocks are: MORGAN STANLEY with ownership of 56,751,601, which is approximately -3.704% of the company’s market cap and around 62.40% of the total institutional ownership; GQG PARTNERS LLC, holding 45,692,830 shares of the stock with an approximate value of $821.56 million in IBN stocks shares; and INVESCO LTD., currently with $645.09 million in IBN stock with ownership of nearly -3.241% of the company’s market capitalization.

Positions in ICICI Bank Limited stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 194 institutional holders increased their position in ICICI Bank Limited [NYSE:IBN] by around 83,872,522 shares. Additionally, 189 investors decreased positions by around 111,462,185 shares, while 57 investors held positions by with 457,188,485 shares. The mentioned changes placed institutional holdings at 652,523,192 shares, according to the latest SEC report filing. IBN stock had 52 new institutional investments in for a total of 12,878,282 shares, while 39 institutional investors sold positions of 64,429,451 shares during the same period.